ReviewAnnals of hematology2026

Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CAR T-cell therapy: a case report and literature review.

Xin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.